Skip to main content
. 2018 Oct 2;19(11):1057–1064. doi: 10.1080/15384047.2018.1480280

Figure 2.

Figure 2.

Sorafenib decreases caspase-1 expression and represses LPS-stimulated caspase-1 expression through restricting p65 nuclear translocation (A) Western blot analysis indicates that sorafenib decreases caspase-1 in a dose-dependent way. HCCLM3 cells were incubated with 0, 0.5, 1, 5, 10, 20 µm sorafeniib for 24 h. (B) Western blot analysis indicates that sorafenib decreases caspase-1. HepG2 and HCCLM3 cells were incubated with 10 um sorafeniib for 24 h. Protein levels of caspase-1 were analyzed by western blot and normalized to GAPDH. (C) Western blot analysis indicates that sorafenib restricts the nuclear transport of p65. Nuclear protein levels of p65 were analyzed by western blot and normalized to Histone H1. (D,E) Western blot analysis indicates that sorafenib suppresses the nuclear transport of p65 caused by LPS. Nuclear protein levels of p65 were analyzed by western blot and normalized to Histone H1. (F) Representative images show the distribution of p65 was visualized by performing immunofluorescence experiments. Scale bars = 20 µm. (G) q-PCR analysis indicates that sorafenib decreases caspase-1 expression and represses LPS-induced caspase-1 overexpression. (H) Caspase-1 enzymatic activity was measured by caspase-1 activity assays. Data are means ± SEM from 3 independent experiments, * means p < 0.05, ** means p < 0.01, *** means p < 0.001 by unpaired student T test.